# Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Exploring a 32.83% Potential Upside for Investors

- Link: https://www.directorstalkinterviews.com/mirum-pharmaceuticals-inc-mirm-stock-analysis-exploring-a-32-83-potential-upside-for-investors/4121229713
- Published: 2025-12-09T11:33:15+00:00
- Author: Madison Wilson

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) stands as a compelling player within 
the biotechnology sector, particularly for investors interested in companies that
focus on rare and orphan diseases. With a market capitalization of $3.49 billion,
this Foster City, California-based biopharmaceutical company is making strides in
developing and commercializing innovative therapies for conditions with significant
unmet medical needs.

At a current price of $67.9, Mirum’s stock has seen a slight dip of 0.01% recently,
yet it remains within a robust 52-week range of $38.39 to $77.69. For investors 
looking at potential growth, the analyst community’s consensus offers a promising
outlook with a target price range of $80.94 to $95.00. The average target price 
of $90.19 suggests a potential upside of 32.83%, which is a compelling figure for
those evaluating the stock’s future trajectory.

Despite the absence of a trailing P/E ratio and the noted high forward P/E of 178.68,
which may initially raise eyebrows, Mirum’s strong revenue growth of 47.20% indicates
a company on a robust growth path. This growth trajectory is further supported by
a healthy free cash flow of approximately $48.7 million, showcasing the company’s
ability to generate cash amid investment in its promising pipeline.

Mirum’s lead product, LIVMARLI (maralixibat), is already making waves as a treatment
for cholestatic pruritus in patients with Alagille syndrome. This innovative approach
positions Mirum favorably in the healthcare sector, with additional products like
Cholbam and Chenodal further strengthening its portfolio. The company’s pipeline
also includes Volixibat, currently in Phase 2b trials, which could expand its market
reach in the treatment of cholestatic liver diseases.

From a technical perspective, the stock’s 50-day moving average of $71.33 and 200-
day moving average of $57.35 suggest recent volatility, yet the RSI of 36.15 indicates
the stock may be nearing oversold territory, potentially providing a buying opportunity
for investors. The MACD at -0.59 with a signal line at -0.23 reinforces the potential
for a trend reversal should positive momentum build.

Analyst sentiment towards Mirum is overwhelmingly positive, with 10 buy ratings 
and no hold or sell recommendations. This optimism reflects confidence in Mirum’s
strategic focus and potential market impact of its therapies. While the company 
does not currently offer dividends, the reinvestment of capital into drug development
and commercialization efforts could yield substantial long-term value.

Mirum Pharmaceuticals, with its focus on debilitating diseases and a robust pipeline,
represents a noteworthy opportunity for investors seeking exposure to the biotechnology
space. Its potential upside, bolstered by strong analyst ratings and innovative 
products, makes Mirum a stock to watch closely as it continues to navigate the complexities
of drug development and commercialization.

Share on:
